Anuh Pharma Reports FY26 Financial Results

Anuh Pharma announced its financial results for the fiscal year ending March 31, 2026. The company reported a notable increase in revenue, reaching ₹771.66 crore, up from ₹661.51 crore in the previous fiscal year, FY2025. Despite this topline growth, the company's Profit After Tax (PAT) experienced a decline, falling to ₹41.05 crore from ₹47.35 crore in FY2025. Basic Earnings Per Share (EPS) also saw a reduction, from ₹4.72 to ₹4.10.

Board Approves Results and Recommends Dividend

The Board of Directors convened on May 20, 2026, to approve the audited financial statements for FY2026. A key decision was the recommendation of a final dividend payment of ₹1.50 per equity share. This proposal is set to be presented to shareholders for approval at the upcoming Annual General Meeting (AGM).

Leadership and Operational Appointments

In addition to the financial review, the board confirmed key leadership appointments. Directors Mr. Bipin Nemchand Shah and Mr. Arun Lalchand Todarwal were re-appointed, ensuring continuity in governance. Furthermore, Mr. P. N. Rao has been appointed as the General Manager - Quality, with his role commencing on June 1, 2026, indicating a strategic focus on enhancing quality control measures.

Financial Performance Context

The FY2026 performance highlights a mixed financial outcome. While the revenue growth suggests expanding business operations, the contraction in profit and EPS warrants attention. The company has also appointed internal and cost auditors for the FY2026-27 period, underscoring ongoing financial oversight.

Shareholder Actions and Future Outlook

Shareholders will be asked to vote on the proposed dividend at the AGM scheduled for August 12, 2026. The record date for determining eligible shareholders for this dividend is August 5, 2026. Investors will be closely monitoring the company's strategy to address the profit decline and the potential re-classification of promoter shares to the public category. The appointment of a new quality head is expected to strengthen operational standards moving forward.

Key Financial Metrics Comparison:

• Revenue: ₹771.66 crore (FY2026) vs. ₹661.51 crore (FY2025)
• PAT: ₹41.05 crore (FY2026) vs. ₹47.35 crore (FY2025)
• Basic EPS: ₹4.10 (FY2026) vs. ₹4.72 (FY2025)